Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Crossref DOI link: https://doi.org/10.1186/s43556-022-00110-2
Published Online: 2022-12-21
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Li, Qingfang
Li, Zhihui
Luo, Ting
Shi, Huashan http://orcid.org/0000-0002-9958-9892
Text and Data Mining valid from 2022-12-21
Version of Record valid from 2022-12-21
Article History
Received: 15 September 2022
Accepted: 10 November 2022
First Online: 21 December 2022
Declarations
:
: Not applicable.
: All authors declare that they have no conflicts of interest.